AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JUN 2 - (NewsRx.com & NewsRx.net) -- Researchers report two new tumor-specific antigenic peptides that are encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2.
According to a study from Belgium, "We have identified two antigens recognized by several melanoma-specific cytolytic T lymphocyte clones isolated from a melanoma patient with a clinical history of tumor regression after immunotherapy. Both antigens are presented by HLA-A2 and encoded by gene MAGE-C2, a cancer-germline gene shown previously to be silent in normal somatic tissues and expressed in 40% of melanomas and in other tumor types.
"One antigen corresponds to peptide ALKDVEERV[subscript]336-344, whereas the other corresponds to peptide LLFGLALIEV[subscript]191-200," reported Wenbin Ma and colleagues at the Ludwig Institute for Cancer Research. "The CTL clones recognizing these 2 peptides also recognized allogeneic tumor cell lines expressing MAGE-C2 and HLA-A2. These 2 new peptides are the first known MAGE-C ...
Source: HighBeam Research, Tumor-specific antigens are encoded by gene MAGE-C2.